NOV 09, 2020 8:33 AM PST

A Prognostic Expression Profile for Osteosarcoma

WRITTEN BY: Jasper Cantrell

Tireless research goes into every cancer diagnostic tools and new therapy. Many types of cancer have made giant steps forward due to these efforts, but many of the more rare or complex cancers lag behind.

Osteosarcoma is a bone cancer and one of the most lethal cancers in the world. Not only is its incidence on the rise, but the survival rates are still what they were decades ago. As it stands, many of the diagnostic and therapeutic tools for osteosarcoma, and other of the rarer cancers, are in desperate need of an update.

One team from Qinghai University in China had an idea for a prognostic test. You see, many cancers tend to manipulate the environment surrounding tumors to stimulate the tumor’s survival and growth. The most common way it does this is by tricking the body’s immune system.

In a new study, the team investigated how osteosarcoma affected the expression of immune-related genes (IRG) in a dataset of osteosarcoma patients. The idea was that osteosarcoma could manipulate the immune system and change the expression of genes in the immune system. They reasoned that these changes could be identified and used to create a sort of genetic profile for diagnostic or prognostic purposes.

To do this, the team analyzed data taken from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) and Genotype-Tissue Expression (GTEx) databases. They identified over 600 differentially expressed IRGs, and slowly began to isolate the set that could best be used as a prognostic profile. They ended up with a group of 13 differentially expressed IRGs that could predict the overall survival of osteosarcoma patients. The profile even outperformed other predictive markers currently used today.

In this study, the team of scientists managed to identify a profile of 13 differentially expressed immune-related genes that could act as a prognostic test for patients with osteosarcoma that outperformed standard tests today. Several studies support that immune-related genes are related to osteosarcoma progression and metastasis, so it stands to reason that they could also be used as a prognostic signature for osteosarcoma progression.

The study concludes, “In summary, we developed an IRGs signature that is a prognostic indicator in OS patients, and further verified it in an independent cohort. Hence, the signature might serve as potential prognostic indicator to identify outcome of OS and facilitate personalized management of the high-risk patients.”

Sources: Nature Scientific Reports, UPMC

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
JAN 12, 2021
Clinical & Molecular DX
Portable Sequencer Ensures All the Cancer Cells Are Gone
JAN 12, 2021
Portable Sequencer Ensures All the Cancer Cells Are Gone
Surgeons remove a tumor from the abdominal cavity of a patient. But how can they be certain that all the cancer cells we ...
JAN 20, 2021
Cancer
Screen yourself for colorectal cancer in your own home
JAN 20, 2021
Screen yourself for colorectal cancer in your own home
Is an at-home colorectal cancer test possible? Researchers from the University of Exeter and the Cancer Research UK CanT ...
JAN 21, 2021
Cancer
Whole body MRI shown to be most sensitive in detecting myeloma
JAN 21, 2021
Whole body MRI shown to be most sensitive in detecting myeloma
New research suggests that whole body magnetic resonance imaging (WBMRI) is a more effective detection method than other ...
FEB 01, 2021
Cancer
Nanoparticle drug delivery to treat pancreatic cancer
FEB 01, 2021
Nanoparticle drug delivery to treat pancreatic cancer
Research published last month in the journal Molecular Pharmaceutics details a new mechanism for delivering pancreatic c ...
FEB 14, 2021
Cancer
Your daily commute exposes you to these two carcinogens
FEB 14, 2021
Your daily commute exposes you to these two carcinogens
New research from UC Riverside reports alarming findings on the risks of exposure to carcinogenic chemicals from time sp ...
MAR 04, 2021
Clinical & Molecular DX
Is the Cancer Treatment Working? Liquid Biopsies Provide Answers.
MAR 04, 2021
Is the Cancer Treatment Working? Liquid Biopsies Provide Answers.
A newly-developed tool could help physicians monitor the performance of colorectal cancer therapies simply by examining ...
Loading Comments...